Interaction Between Olaparib and Regorafenib in Rats
Author Information
Author(s): Szkutnik-Fiedler Danuta, Karbownik Agnieszka, Otto Filip, Maciejewska Julia, Kuźnik Alicja, Grabowski Tomasz, Wolc Anna, Grześkowiak Edmund, Stanisławiak-Rudowicz Joanna, Szałek Edyta
Primary Institution: Poznań University of Medical Sciences
Hypothesis
The study aimed to evaluate the bilateral pharmacokinetic interactions of Olaparib and Regorafenib and its active metabolites after a single administration in healthy rats.
Conclusion
Olaparib significantly affects the pharmacokinetics of Regorafenib and its active metabolites in rats after co-administration, which may have clinical relevance.
Supporting Evidence
- Olaparib and Regorafenib are both metabolized by the CYP3A4 isoenzyme.
- The pharmacokinetic parameters of Regorafenib increased significantly when co-administered with Olaparib.
- Regorafenib significantly affected the pharmacokinetics of Olaparib.
- The study used a controlled animal model to assess drug interactions.
- Results indicate potential clinical relevance for drug interactions in cancer therapy.
Takeaway
This study looked at how two cancer drugs, Olaparib and Regorafenib, affect each other when given together to rats, showing that they can change how the body processes each drug.
Methodology
The study was performed in male Wistar rats divided into three groups, with pharmacokinetic parameters determined by ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS).
Limitations
The study's findings may not directly translate to humans due to species differences in drug metabolism and pharmacokinetics.
Participant Demographics
Male Wistar rats, 14 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website